The BGM Galectin-3 Blood Test is FDA-cleared as an aid in assessing the prognosis of CHF patients*.
* in conjunction with clinical evaluation.
Prevalance of Galectin-3 Mediated HF
30–50% of CHF patients have a common and serious form of heart failure known as galectin-3 mediated heart failure.
Impact of Galectin-3 Mediated HF
“Galectin-3 testing may be of benefit in programs aiming to reduce hopital readmission rates for HF.”
Rudolf A. De Boer, MD. PHD
University Medical Center Groningen, Groningen NL
Galectin-3 in Chronic HF
Galectin-3 defines a distinct form of heart failure characterized by progressive fibrosis.
Galectin-3 mediated heart failure
Heart failure is a condition caused by multiple medical problems and risk factors. Studies have shown that in 30–50% of chronic heart failure patients there is an underlying and inherently progressive disease mediated by the protein galectin-3.
In the US alone, heart failure is expected to cost the healthcare system over an estimated $39 billion. A significant contributor is the rehospitalization rate of 40% for HF patients. Galectin-3 was found to be a strong independent predictor of rehospitalization for HF patients.